No profile data available.
Cellectis S.a. (CLLS) is a healthcare company in the blood cancer treatment drugs industry, based in Paris, France, with about 224 full-time employees.
It reported revenue of $72.95 million for fiscal year 2025, up 75.8% from fiscal year 2024, and net income of -$67.59 million. Its market capitalization was $126.92 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Cellectis reported $72.95 million in revenue for fiscal year 2025, up 75.8% from $41.51 million in fiscal year 2024.
$126.92 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Sellas Life Sciences Group, Inc. (SLS), ADC Therapeutics SA (ADCT), Lyell Immunopharma, Inc. (LYEL), Atara Biotherapeutics, Inc. (ATRA).